Béa Fertility secures £2.5m led by Octopus Ventures to launch at-home treatments
The funding round was led by Octopus Ventures with backing from JamJar and Forward Partners.
Béa Fertility develops clinical-grade fertility treatments designed for use in the home. The company aims to widen access to reproductive care through affordable alternatives to traditional clinical procedures.
Béa Fertility has secured £2.5m in funding led by Octopus Ventures, with participation from JamJar, Forward Partners, Calm/Storm, and Q Ventures. The capital will be deployed to launch the company's at-home fertility treatment kits for early adopters in the UK and support an upcoming pilot scheme within the NHS.
Founded by Tess Cosad and George Thomas, the femtech startup provides clinical-grade treatments like intracervical insemination as a more accessible alternative to invasive procedures such as IVF. The latest injection of capital brings the firm's total funding to date to $4.2m as it seeks to address gaps in reproductive healthcare.
From the founder
"This latest injection of funding – from experienced investors with a proven track record of backing successful fertility and femtech businesses – will enable us to get our pioneering treatment in the hands of the people who need it most. We can’t wait for people to try it."
Tess Cosad
CEO and co-founder at Béa Fertility
Investor perspective
"At Octopus Ventures we back founders who are changing the world for the better. We invest where we can make the greatest positive impact. When it comes to starting a family there are few things in life more meaningful than this. Béa Fertility who is reimagining the fertility care pathway, was a clear vision we wanted to get behind. We’re delighted to have joined Tess and her team on this journey."
Kirsten Connell
Partner, Octopus Ventures
Use of funds
- 01Continue product development
Investors
Categories
About the company
Béa Fertility
Béa Fertility provides clinical-grade fertility treatments for home use.